Nostos Genomics

Nostos Genomics is a biotechnology startup based in Germany that aims to revolutionize genetic testing. With their slogan "We turn data into genomic insights," the company is focused on partnering with genetic testing labs to provide faster and clearer diagnoses for individuals with genetic diseases. This is particularly crucial as over 300 million people globally are affected by rare genetic diseases, yet the journey to diagnosis often takes more than 5 years, with many individuals being misdiagnosed or left undiagnosed altogether. Nostos Genomics recognizes the potential of new technology in making genetic testing more accessible and in the development of targeted therapies for previously untreatable disorders. However, the interpretation of mutations remains a bottleneck in the process, leading to laborious and inconclusive results. In response, the company has developed a CE-certified platform that leverages machine learning and synthetic biology to automate the interpretation of mutations, promising to diagnose more individuals in a shorter timeframe. The promising impact of Nostos Genomics has attracted a €5.00M Seed Round investment on 03 February 2022, with participation from notable investors including Entrepreneur First, Frontline Ventures, 42CAP, Faber, WENVEST Capital, and Amino Collective. This demonstrates confidence in the company's potential to address a critical need in the healthcare industry and signifies a significant milestone in their journey of leveraging technology to improve genetic diagnostics and patient outcomes.